9-27-04

IFW

CERTIFICATE OF MAILING

I HEREBY CERTIFY THAT THIS PAPER AND THE DOCUMENTS REFERRED AS BEING ATTACHED OR CHICLOSED HEREWITH ARE BEING DEPOSITED WITH THE UNITED STATES POSTAL OFFICE ON AS EXPRESS MAIL ADDRESSED TO: MAIL STOP AMENDMENT COMMISSIONER FOR

PATENTS, PO-BOX 1450, ALEXANDRIA, VA 22313-1450

Elaine C. Stracker

PATENT

Attorney's Docket No.: 00023.04CON

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Rabinowitz et al.

Serial No.:

10/814,998

Filed:

3/31/2004

Title

DELIVERY OF MUSCLE RELAXANTS THROUGH AN

INHALATION ROUTE

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Dear Sir:

In accordance with their continuing duty of disclosure under 37 CFR §§ §1.97, 1.98 and 1.56, Applicants hereby submit for consideration in the above-identified application the enclosed references. The Information Disclosure statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.

For the convenience of the Examiner, the references are listed on a PTO Form 1449 (attached) and copies thereof are enclosed. Applicants would appreciate the Examiner initialing and returning the Form PTO-1449, indicating that the information has been considered and made of record herein.

In the unlikely event that the transmittal letter is separated from this document and the Patent Office determines than an extension and/or other relief is required, Applicants petition for any required relief including any extensions of time and authorizes the Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to **Deposit Account No. 502731**. Please direct all correspondence to the following customer number.

Respectfully submitted,

SF	P	9	Λ	20	MA

Date:

Elaine C. Stracker J.D., Ph.D., Reg. 43,166

Alexza Molecular Delivery Corporation 1001 East Meadow Circle Palo Alto, CA 94303

TEL: (650) 687-3905

FAX: (650) 687-3999

PTO/SB/21 (08-03)

Under the Paperwork Reduction Act of 1995, no	persons	are required	Patent and Tradem	ark Offic	ce: U.S. DEPARTMENT OF COMMERCE is it displays a valid OMB control number.
			Application Number	10/8	314,998
TRANSMITT	AL		Filing Date	3/31	
FORM			First Named Inventor	Josi	nua D. Rabinowitz
(to be used for all correspondence after	r initial fi	ling)	Art Unit	Not	yet known
			Examiner Name	To	be assigned
Total Number of Pages in This Submission			Attorney Docket Number	000	23.04CON
		ENCLOS	JRES (check all that apply)	
Fee Transmittal Form		Drawing(s)		After Allowance communication to Group
Fee Attached		Licensing-related Papers			Appeal Communication to Board of Appeals and Interferences
Amendment / Reply		Petition			Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
After Final			o Convert a al Application		Proprietary Information
Affidavits/declaration(s)			Attorney, Revocation of Correspondence		Status Letter
Extension of Time Request		Terminal	Disclaimer	X	Other Enclosure(s) (please identify below):
Express Abandonment Request Request f		for Refund			
Information Disclosure Statement CD,		CD, Num	aber of CD(s)		·
Certified Copy of Priority Document(s)	Rem	arks			<u> </u>
Response to Missing Parts/			_		

	SIGNATURE OF APPLICANT, ATTORNEY, OR AGEN	Т	
Firm or Individual name	ALEXZA MDC, 1001 East Meadow Circle, Palo Alto, CA 94303 Elaine C Stracker, Ph.D., J.D. Telephone (650)-687-3905	Customer Number 37485	
Signature	Win O Sech	·	
Date	SEP. 2 4 2004		

Info. Discl. Statement (2 pp.) Form 1449 (3 copies , 7 pages each) Copy of : Kreferences / 64

Return postcard

Incomplete Application

Response to Missing Parts

under 37 CFR 1.52 or 1.53

CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the

Typed or printed name	Elaine C. Stracker			
Signature	Elen	(1- Street	Date	SEP. 2 4 2004

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

O 1 P E SEP 2 1 2004 By Parm PTO-14498

TION DISCLOSURE CITATION
IN AN APPLICATION

(Use several sheets if necessary)

Docket Number: 0023.04CON Application Number: 10/814,998

Applicant: Joshua D. RABINOWITZ et al.

Filing Date: 3/31/2004 Group Art Unit: Not Yet Known

U.S. PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date ·	Document No.	Name	Class	Subclass	Filing Date If Appropriate
	1.	02/02/1971	3,560,607	Hartley et al.			
	2.	10/19/1976	3,987,052	Hester, Jr.			
	3.	05/27/1980	Re. 30,285	Babington			
	4.	01/23/1990	4,895,719	Radhakrishnun et al.			•
	5.	09/17/1991	5,049,389	Radhakrishnun			
•	6.	12/27/1994	5,376,386	Ganderton			
	7,	02/14/1995	5,388,574	Ingebrethsen			
····	8.	08/13/1996	5,544,646	Lloyd et al.			
	9.	12/09/1997	5,694,919	Rubsamen et al.			
	10.	04/07/1998	5,735,263	Rubsamen et al.			
	11.	04/14/1998	5,738,865	Baichwal et al.			
	12.	06/02/1998	5,758,637	Ivri et al.			
	13.	06/29/1999	5,915,378	Lloyd et al.			
	14.	08/10/1999	5,934,272	Lloyd et al.			
	15.	09/28/1999	5,957,124	Lloyd et al.			
	16.	10/05/1999	5,960,792	Lloyd et al.			
	17.	11/30/1999	5,993,805	Sutton et al.			,
	18.	03/28/2000	6,041,777	Faithfull et al.			
	19.	04/18/2000	6,051,566	Bianco			
	20.	08/01/2000	6,095,153	Kessler et al.			
	21.	08/15/2000	6,102,036	Slutsky et al.	·		
	22.	06/05/2001	6,241,969	Saidi et al.			
	23.	07/03/2001	6,255,334	Sands			
	24.	01/14/2003	6,506,762	Horvath et al.			
	25.	02/04/2003	6,514,482	Bartus et al.			
·	26.	07/15/2003	6,591,839	Meyer et al.			

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

PTO/SB/ 08 (2-92)

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Form PTO-1449		Docket Number: 0023.04CON Application Number: 10/814,998			: 10/814,998
INFORMATION DISCLOSURE CIT IN AN APPLICATION	ATION Applicant	: Joshua I	D. RABINOW	ITZ et al.	
(Use several sheets if necessary)	Filing Da	te: 3/31/200)4 Group	p Art Unit:	Not Yet Known
		•			
	· · · · · · · · · · · · · · · · · · ·				
		orth et al.			
	2/0037828 Wilson				
	2/0058009 Bartus	et al.			
30. 07/04/2002 US 200	2/0086852 Cantor				
31. 08/22/2002 US 200	2/0112723 Schust	ter et al.			
32. 11/28/2002 US 200	2/0176841 Barker	et al.			
33. 01/02/2003 US 200	3/0004142 Prior e	et al.			
34. 02/13/2003 US200	3/0032638 Kim et	t al.			
RELATED ALEXZA MOLECU	AR DELIVERY C	ORPORATION	I PATENT	DOCUM	ENTS
	3,876 Hale et a				
36. 08/04/2003 10/6	3,877 Hale et a	al.			
37. 12/30/2003 10/7	9,537 Rabinov	vitz et al.			
38. 12/30/2003 10/7	9,539 Rabinov	vitz et al.			
39. 01/27/2004 10/7	66,149 Rabinov	vitz et al.			
40. 01/27/2004 10/7	66,279 Rabinow	vitz et al.	·		
41. 01/27/2004 10/7	66,566 Rabinov	vitz et al.			
42. 01/27/2004 10/7	66,574 Rabinov	vitz et al.			
43. 01/27/2004 10/7	66,634 Rabinov	vitz et al.			
44. 01/27/2004 10/7	66,647 Rabinov	vitz et al.			
45. 01/28/2004 10/7	7,115 Rabinov	vitz et al.			
46. 01/29/2004 10/7	8,205 Rabinov	vitz et al.			
47. 01/29/2004 10/7	8,220 Rabinov	vitz et al.			
48. 01/29/2004 10/7	8,281 Rabinov	vitz et al.			
49. 01/29/2004 10/7	8,293 Rabinov	vitz et al.			
50. 01/30/2004 10/7	59,046 Rabinov	vitz et al.			
51. 01/30/2004 10/7	59,051 Rabinov	vitz et al.			
52. 01/29/2004 10/7	59,157 Rabinov	vitz et al.			
53. 01/29/2004 10/7	59,197 Rabinov	vitz et al.			
54. 02/09/2004 10/7	75,583 Rabinov	vitz et al.			
55. 02/09/2004 10/7	75,586 Rabinov	vitz et al.			
EXAMINER:	Г	DATE CONSIDER	ED:		
EXAMINER: Initial if citation considered, whether conformance and not considered. Include a copy of	or not the citation conforthis form with next comm	ms with MPEP 609.	Draw a line the	rough the cita	tion if not in

Form PTO-1449		Docket Number: 0023.04CON Application Number: 10/814,998			r: 10/814,998	
	TION DISCLOS N AN APPLICA	URE CITATION TION	Applicant:	Joshua D. RAB	INOWITZ et al.	
	(Use several sheets if nec	cessary)	Filing Date:	3/31/2004	Group Art Unit:	Not Yet Known
56.	03/03/2004	10/791,915	Hale et al.			
57.	03/03/2004	10/792,001	Rabinowitz et al.			
58.	03/03/2004	10/792,012	Hale et al.	•		
59.	03/03/2004	10/792,012	Rabinowitz et al.			
60.	03/03/2004	10/792,013	Hale et al.			
61.	03/03/2004	10/792,239	Hale et al.			
	03/03/2004	10/732,233	Rabinowitz et al			
62.	03/31/2004	10/813,721	Rabinowitz et al			
	03/31/2004	10/813,722	Rabinowitz et al			
, 64.	03/31/2004	10/815,527	Rabinowitz et al			
65. 66.	04/01/2004	10/816,407	Rabinowitz et al			
67.	04/01/2004	10/816,492	Rabinowitz et al			
68.	04/01/2004	10/816,567	Rabinowitz et al			
69.	08/04/2004	10/810,307	Hale et al.	-		· · ·
70.	01/23/2003	US 2003/0015196	Hodges et al.			-
70.	04/03/2003	US 2003/0062042	Wensley et al.			
71.	11/13/2003	US 2003/0002042	Hale et al.			
73.	01/02/2003	US 2003/0209240	Rabinowitz et al			
	01/02/2003	US 2003/0005924	Rabinowitz et al			
74.	01/09/2003	US 2003/0005925	Hale et al.	•		
75.		US 2003/0003923	Rabinowitz et al			
76.	01/09/2003	US 2003/0007934	Rabinowitz et al			
77.		US 2003/0007934 US 2003/0012737	Rabinowitz et al			
78.	01/16/2003	US 2003/0012737	Rabinowitz et al			
79.	01/16/2003	US 2003/0012738	Rabinowitz et al			
80.	1/16/2003	US 2003/0012740	Rabinowitz et al			
81.	01/23/2003	US 2003/0015190	Rabinowitz et al			
82.	01/23/2003	US 2003/0013190	Rabinowitz et al			
83.	01/23/2003	US 2003/0017114	Rabinowitz et al			<u> </u>
84.	01/23/2003	US 2003/0017116	Rabinowitz et al		· ·	
85.	01/23/2003	03 2003/001/110	Kaumowitz et ai			<u> </u>
EXAMINER:			DATE CO	ONSIDERED:		

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in

conformance and not considered. Include a copy of this form with next communication to applicant...

PTO/SB/ 08 (2-92)

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Applicant: Joshua D. RABINOWITZ et al. Filing Date: 3/31/2004 Group Art Unit: Not Yet Know abinowitz et al. Abinowitz et al. Abinowitz et al.
abinowitz et al.
abinowitz et al.
abinowitz et al.
him avviter at a1
ioinowitz et ai.
abinowitz et al.
abinowitz et al.
abinowitz et al.
ale et al.
odges et al.
abinowitz et al.
ale et al.
abinowitz
abinowitz et al.
abinowitz et al.
odges et al.
ale et al.
ale et al.
ale et al.
abinowitz et al.
abinowitz et al.
abinowitz et al.
abinowitz et al.
abinowitz et al.
abinowitz et al.
abinowitz et al.
abinowitz et al.
abinowitz et al.
abinowitz et al.

Form PTO-1449

INFORMATION DISCLOSURE CITATION IN AN APPLICATION

(Use several sheets if necessary)

Docket Number:	0023.04CON	Application Number: 10/814,998		
Applicant:	Joshua D. R.A	BINOWITZ et al.		
Filing Date:	3/31/2004	Group Art Unit:	Not Yet Known	

FOREIGN PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Country	Class	Subclass	Translation YES NO
	113.	03/14/1990	EP 0 358 114	Europe			
	114.	07/03/2001	EP 1 080 720	Europe			
	115.	08/29/2001	EP 0 606 486	Europe			
	116.	04/11/1996	WO 96/09846	WIPO			
	117.	05/09/1996	WO 96/13161	WIPO			
	118.	05/09/1996	WO 96/13290	WIPO			·
	119.	05/09/1996	WO 96/13291	WIPO			
	120.	05/09/1996	WO 96/13292	WIPO			
	121.	10/03/1996	WO 96/30068	WIPO			
	·122.	08/07/1997	WO 97/27804	WIPO			
······································	123.	05/28/1998	·WO 98/22170	WIPO			
	124.	07/23/1998	WO 98/31346	WIPO			
•	125.	08/27/1998	WO 98/36651	WIPO			
	126.	04/08/1999	WO 99/16419	WIPO			
	127.	12/16/1999	WO 99/64094	WIPO			
	128.	01/06/2000	WO 00/00176	WIPO			
	129.	01/06/2000	WO 00/00215	WIPO			
	130.	05/18/2000	WO 00/27363	WIPO			
	131.	05/25/2000	WO 00/29053	WIPO			
	132.	09/17/2000	WO 00/47203	WIPO			
	133.	11/02/2000	WO 00/64940	WIPO			
	134.	11/09/2000	WO 00/66084	WIPO			
	135.	11/09/2000	WO 00/66206	WIPO			
	136.	12/21/2000	WO 00/76673	WIPO			
	137.	01/25/2001	WO 01/05459	WIPO ·			
	138.	05/10/2001	WO 01/32144	WIPO			
	139.	03/28/2002	WO 02/24158	WIPO			

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

PTO/SB/ 08 (2-92)

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION

(Use several sheets if necessary)

			Dilect o of 7
Docket Number: 0023.04CON		Application Number	er: 10/814,998
Applicant:	Joshua D. RA	BINOWITZ et al.	W.
Filing Date:	3/31/2004	Group Art Unit:	Not Yet Known

OTHER DOCUMENTS

(including author, title, Date, Pertinent Pages, Etc.)

Examiner Initials	Ref. No.	Title
	140.	Bennett, R.L. et al. (1981). "Patient-Controlled Analgesia: A New Concept of Postoperative Pain Relief," <i>Annual Surg.</i> 195(6):700-705.
	141.	Carroll, M.E. et al. (1990), "Cocaine-base smoking in rhesus monkeys: reinforcing and physiological effects," <i>Psychopharmacology</i> (Berl). 102:443-450.
	142.	Clark, A. and Byron, P. (1986). "Dependence of Pulmonary Absorption Kinetics on Aerosol Particle Size," Z. Erkrank. 166:13-24.
	143.	Darquenne, C. et al. (1997). "Aerosol Dispersion in Human Lung: Comparison Between Numerical Simulations and Experiments for Bolus Tests," <i>American Physiological Society</i> . 966-974.
	144.	Davies, C.N. et al. (May 1972). "Breathing of Half-Micron Aerosols," <i>Journal of Applied Physiology</i> . 32(5):591-600.
	145.	Dershwitz, M., M.D., et al. (September 2000). "Pharmacokinetics and Pharmacodynamics of Inhaled versus Intravenous Morphine in Healthy Volunteers," <i>Anesthesiology</i> . 93(3): 619-628.
	146.	Finlay, W.H. (2001). "The Mechanics of Inhaled Pharmaceutical Aerosols", Academic Press: San Diego Formula 2.39. pp.3-14 (Table of Contents). pp. v-viii.
	147.	Gonda,I. (1991). "Particle Deposition in the Human Respiratory Tract," Chapter 176, <u>The Lung: Scientific Foundations</u> . Crystal R.G. and West, J.B. (eds.), Raven Publishers, New York. pp. 2289-2294.
	148.	Hatsukami D, et al. (May 1990) "A method for delivery of precise doses of smoked cocaine-base to humans." Pharmacology Biochemistry & Behavior. 36(1):1-7.
	149.	Heyder, J. et al. (1986). "Deposition of Particles in the Human Respiratory Tract in the Size Range 0.005-15 μm," J. Aerosol Sci. 17(5):811-822.
	150.	Huizer, H., "Analytical studies on illicit heron. V. Efficacy of volatilization during heroin smoking." <i>Pharmaceutisch Weekblad Scientific Edition</i> (1987). 9(4):203-211.
	151.	Hurt, R.D., MD and Robertson, C.R., PhD, (October 1998). "Prying Open the Door to the Tobacco Industry's Secrets About Nicotine: The Minnesota Tobacco Trial," JAMA 280(13):1173-1181.
	152.	Lichtman, A.H. et al. (1996). "Inhalation Exposure to Volatilized Opioids Produces Antinociception in Mice," Journal of Pharmacology and Experimental Therapeutics. 279(1):69-76.
	153.	Martin, B.R. and Lue, L.P. (May/June 1989). "Pyrolysis and Volatilization of Cocaine," <i>Journal of Analytical Toxicology</i> 13:158-162.

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

PTO/SB/08 (2-92) Sheet 7 of 7

TION Applicant:	V 1 D D 1		Application Number: 10/814,998	
ATION Applicant:	Joshua D. RA	BINOWITZ et al.		
Filing Date:	3/31/2004	Group Art Unit:	Not Yet Known	
5:195-201.				
Studies With Drugs of	Abuse, "NIDA Ro	esearch Monogra _l	ph, (1997)	
Pharmacological effects of and Alcohol Dependen	of methamphetam ece. 53:111-120.	ine and other stim	ulants via	
Office Action mailed 8/13/2003 for US application 10/153,313 filed 05/21/2002 "DELIVERY OF BENZODIAZEPINES THROUGH AN INHALATION ROUTE".				
Pankow, J.F. et al. (1997). "Conversion of Nicotine in Tobacco Smoke to Its Volatile and Available Free-Base Form Through the Action of Gaseous Ammonia," <i>Envron. Sci. Technol.</i> 31:2428-2433.				
Pankow, J. (March 2000). ACS Conference-San Francisco-3/26/00. Chemistry of Tobacco Smoke. pp. 1-8.				
Seeman, J. et al. (1999). "The Form of Nicotine in Tobacco. Thermal Transfer of Nicotine and Nicotine Acid Salts to Nicotine in the Gas Phase," J. Agric. Food Chem. 47(12):5133-5145.				
Sekine, H. and Nakahara, Y. (1987). "Abuse of Smoking Methamphetamine Mixed with Tobacco: 1. Inhalation Efficiency and Pyrolysis Products of Methamphetamine," <i>Journal of Forensic Science</i> 32(5):1271-1280.				
Vapotronics, Inc. (1998) located at http://www.vapotronics.com.au/banner.htm , 11 pages, (visited on June 5, 2000).				
ecember1997). "Morphi vel Aerosol Delivery Sy	ber1997). "Morphine Pharmacokinetics after Pulmonary Lerosol Delivery System," Clinical Pharmacology & Therapeutics			
"Generation of Stable T dine, and Demonstration . 55(2):237-248.	Demonstration of Their Biological Activity." Pharmacology			
	M.E., (1996). "Smoked he: 195-201." Studies With Drugs of tharmacological effects of and Alcohol Dependent (2003 for US application ROUGH AN INHALA" "Conversion of Nicotine the Action of Gaseous A ACS Conference-San Fill The Form of Nicotine in otine in the Gas Phase," Y. (1987). "Abuse of Sn Pyrolysis Products of Mocated at http://www.vajecember1997). "Morphis vel Aerosol Delivery Sy "Generation of Stable Tidine, and Demonstration	M.E., (1996). "Smoked heroin self-admini: 195-201. Studies With Drugs of Abuse, "NIDA Recognition of Allohol Dependence." Signal Alcohol Dependence. 53:111-120. /2003 for US application 10/153,313 filed ROUGH AN INHALATION ROUTE". "Conversion of Nicotine in Tobacco Smothe Action of Gaseous Ammonia," Envroy ACS Conference-San Francisco-3/26/00. The Form of Nicotine in Tobacco. Thermstotine in the Gas Phase, "J. Agric. Food Company of Methamphetamine, "Decated at http://www.vapotronics.com.au/ecember1997). "Morphine Pharmacokine wel Aerosol Delivery System," Clinical Paragraphics and Demonstration of Their Biological "Generation of Stable Test Atmospheres dine, and Demonstration of Their Biological Paragraphics of Stable Test Atmospheres dine, and Demonstration of Their Biological Paragraphics of Stable Test Atmospheres dine, and Demonstration of Their Biological Paragraphics of Stable Test Atmospheres dine, and Demonstration of Their Biological Paragraphics of Stable Test Atmospheres dine, and Demonstration of Their Biological Paragraphics of Stable Test Atmospheres dine, and Demonstration of Their Biological Paragraphics of Stable Test Atmospheres dine, and Demonstration of Their Biological Paragraphics of Stable Test Atmospheres dine, and Demonstration of Their Biological Paragraphics of Stable Test Atmospheres dine, and Demonstration of Their Biological Paragraphics of Stable Test Atmospheres dine, and Demonstration of Their Biological Paragraphics of Stable Test Atmospheres dine, and Demonstration of Their Biological Paragraphics of Stable Test Atmospheres dine, and Demonstration of Their Biological Paragraphics of Stable Test Atmospheres dine, and Demonstration of Their Biological Paragraphics of Stable Test Atmospheres dine, and Demonstration of Their Biological Paragraphics of Stable Test Atmospheres dine, and Demonstration of Their Biological Paragraphics of Stable Test Atmospheres dine, and Demonstration of Their Biological Paragraphics of Stable Test Atmospheres dine, and Demonstration of Test Atmo	M.E., (1996). "Smoked heroin self-administration in rhesus: 195-201. Studies With Drugs of Abuse, "NIDA Research Monographer and Alcohol Dependence. 53:111-120. /2003 for US application 10/153,313 filed 05/21/2002 "DEI ROUGH AN INHALATION ROUTE". "Conversion of Nicotine in Tobacco Smoke to Its Volatile the Action of Gaseous Ammonia," Envron. Sci. Technol. 31 ACS Conference-San Francisco-3/26/00. Chemistry of Tobacto of the Gas Phase, "J. Agric. Food Chem. 47(12):5133 Y. (1987). "Abuse of Smoking Methamphetamine Mixed we Pyrolysis Products of Methamphetamine," Journal of Forein ocated at http://www.vapotronics.com.au/banner.htm. , 11 percember 1997). "Morphine Pharmacokinetics after Pulmona vel Aerosol Delivery System," Clinical Pharmacology & Tobactor of Stable Test Atmospheres of Cocaine Base and the dine, and Demonstration of Their Biological Activity." Pharmacology and Demonstration of Their Biological Activity." Pharmacoline, and Demonstration of Their Biological Activity." Pharmacoline in Pharmacology and Demonstration of Their Biological Activity." Pharmacoline, and Demonstration of Their Biological Activity." Pharmacoline in the Gas Phase in the	

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.